A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection

2.50
Hdl Handle:
http://hdl.handle.net/10757/622635
Title:
A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection
Authors:
Allan-Blitz, Lao-Tzu; Hemarajata, Peera; Humphries, Romney M.; Wynn, Adriane; Segura, Eddy R. ( 0000-0003-3580-7712 ) ; Klausner, Jeffrey D.
Citation:
A Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection 2018, 45 (2):87 Sexually Transmitted Diseases
Publisher:
Lippincott Williams and Wilkins
Journal:
Sexually Transmitted Diseases
Issue Date:
Feb-2018
URI:
http://hdl.handle.net/10757/622635
DOI:
10.1097/OLQ.0000000000000698
Additional Links:
http://Insights.ovid.com/crossref?an=00007435-201802000-00004
Abstract:
From the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: lallanblitz@mednet.ucla.edu. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698
Type:
info:eu-repo/semantics/article
Rights:
info:eu-repo/semantics/restrictedAccess
Language:
eng
Description:
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Keywords:
Azithromycin; Ceftriaxone; Ciprofloxacin; DNA topoisomerase (ATP hydrolysing) A; Antibiotic resistance; Antibiotic sensitivity; Chlamydiasis; Cost benefit analysis
ISSN:
0148-5717

Full metadata record

DC FieldValue Language
dc.contributor.authorAllan-Blitz, Lao-Tzues
dc.contributor.authorHemarajata, Peeraes
dc.contributor.authorHumphries, Romney M.es
dc.contributor.authorWynn, Adrianees
dc.contributor.authorSegura, Eddy R.es
dc.contributor.authorKlausner, Jeffrey D.es
dc.date.accessioned2018-02-12T14:44:00Z-
dc.date.available2018-02-12T14:44:00Z-
dc.date.issued2018-02-
dc.identifier.citationA Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infection 2018, 45 (2):87 Sexually Transmitted Diseaseses
dc.identifier.issn0148-5717-
dc.identifier.doi10.1097/OLQ.0000000000000698-
dc.identifier.urihttp://hdl.handle.net/10757/622635-
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.es
dc.description.abstractFrom the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095. E‐mail: lallanblitz@mednet.ucla.edu. Received for publication February 21, 2017, and accepted July 30, 2017. DOI: 10.1097/OLQ.0000000000000698es
dc.formatapplication/pdfes
dc.language.isoenges
dc.publisherLippincott Williams and Wilkinses
dc.relation.urlhttp://Insights.ovid.com/crossref?an=00007435-201802000-00004es
dc.rightsinfo:eu-repo/semantics/restrictedAccesses
dc.subjectAzithromycines
dc.subjectCeftriaxonees
dc.subjectCiprofloxacines
dc.subjectDNA topoisomerase (ATP hydrolysing) Aes
dc.subjectAntibiotic resistancees
dc.subjectAntibiotic sensitivityes
dc.subjectChlamydiasises
dc.subjectCost benefit analysises
dc.titleA Cost Analysis of Gyrase A Testing and Targeted Ciprofloxacin Therapy Versus Recommended 2-Drug Therapy for Neisseria gonorrhoeae Infectiones
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.journalSexually Transmitted Diseaseses
dc.description.fundingFrom the *Division of Infectious Diseases, Department of Medicine, †Department of Laboratory Medicine, David Geffen School of Medicine, Department of Medicine, ‡Fielding School of Public Health, University of California Los Angeles, Los Angeles, CA; §Escuela de Medicina, Universidad Peruana de Ciencias Aplicadas, Lima, Peru; and ¶Division of Infectious Diseases, Department of Medicine, University of California Los Angeles, Los Angeles, CA Conflict of Interest and Sources of Funding: None declared. This research was supported by the United States National Institutes of Health grants R21AI117256 and R21AI109005 as well as the South American Program in HIV Prevention Research NIH/NIMH R25MH087222. Correspondence: Lao-Tzu Allan-Blitz, MD Candidate, 2018, David Geffen School of Medicine, University of California Los Angeles, 10833 Le Conte Ave, Los Angeles, CA 90095es_PE
dc.description.peerreviewRevisión por pareses_PE
All Items in UPC are protected by copyright, with all rights reserved, unless otherwise indicated.